[ad_1]
Shares of Orphazyme A/S ORPH, -41.21%, fell 54.3% in premarket trading Friday, after the Denmark-based biopharmaceutical company said overnight that it had received a “complete response letter” (CRL) from the U.S. Food and Drug Administration regarding its treatment. . For Niemann-Pick type C disease (NPC). CRL said additional qualitative and quantitative evidence is needed to validate and interpret the 5-domain NPC clinical severity scale and ingestion domain, as well as additional data to confirm evidence after a single phase 2/3 trial supporting the benefit-risk assessment of new drug application (NDA). The company was “disappointed” and “disappointed” with the FDA’s decision, which will have a “significant impact” on the financial outlook for this year. The company said its operating loss guidance range had expanded to 670 million DKK to 700 million DKK ($107.4 million to $112.2 million) from 100 million to 150 million DKK. Orphazyme stock made the rounds on social media last week, after the stock surged as much as 1,387% on the day on June 10 before closing 301.5% in highly volatile trade, even as the company said it wasn’t aware of any reason. The stock is up 35.7% year-to-date Thursday, while the iShares Nasdaq Biotechnology ETF IBB is up -0.82% and the S&P 500 SPX is up -1.06%, up 12.4%.
.
[ad_2]
Picture Credit!